3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer - Prostate Cancer - Sexual Health - Urine Problems -

Legislation needed to provide coverage for ED treatment after prostatectomy

Cancer • • Prostate Cancer • • Sexual Health • • Urine ProblemsMay 15, 08

Men who have developed erectile dysfunction (ED) following surgery for prostate cancer usually do not have insurance coverage for ED treatment even though their insurance policies cover surgery for prostate cancer, according to an analysis presented today at the 103rd Annual Scientific Meeting of the American Urological Association. In contrast, federal law requires that insurance companies which cover mastectomy for breast cancer treatment also cover breast reconstruction.

Erectile dysfunction (ED) is a common side effect of radical prostatectomy, though not always permanent, and almost all men experience some degree of ED following this surgery. The impact of ED on self-esteem and body image to prostate cancer patients can be as detrimental as the loss of a breast can be to a woman. However, the Women’s Health and Cancer Rights Act, passed by Congress in 1998, requires that third-party payers who cover mastectomy for breast cancer also cover the costs of breast reconstruction.

“There is compelling evidence that ED treatment leads to improved quality of life for the man and his partner,” said Ira D. Sharlip, M.D., a spokesman for the AUA. Therefore, as in the case of breast reconstruction for women, the cost of ED treatment should most certainly be covered for men.”

A number of treatments for ED are available, including oral pharmacotherapies (approximately $10 per pill), intracavernosal injections ($25 per treatment), intraurethral alprostadil ($25 per treatment), vacuum erection devices ($450) and penile implants ($12,000). On average, breast reconstruction surgeries cost $12,000 to $20,000.

Approximately 60,000 radical prostatectomies and breast reconstruction surgeries are performed each year. Researchers used this patient population to determine healthcare costs for ED therapy over a projected 10-year life expectancy and found that, on average, the costs to treat ED was significantly less than the cost of breast reconstruction. The authors conclude that the time for legislative gender parity in this area has come.

###

In addition to the author, Dr. Sharlip will be on hand to answer questions and provide third-party perspective on the study.

NOTE TO REPORTERS: Experts are available to discuss these studies outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail Wendy Isett at .(JavaScript must be enabled to view this email address).

Hyams ES, Ficile MA, McCullough AR: The time for legislative gender parity has come: an economic argument for insurance reimbursement for erectile dysfunction therapy after radical prostatectomy. J Urol, suppl., 2008; 179: 58k, abstract 166.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 15,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients, including UrologyHealth.org, an award-winning on-line patient education resource, and the American Urological Association Foundation, Inc.

Contact: Lacey Holt
.(JavaScript must be enabled to view this email address)
American Urological Association



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Addressing the needs of young women with disorders of sex development
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site